🇺🇸 Tacrolimus Sustained-release Capsules in United States

8 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Bilirubin Increased — 1 report (12.5%)
  2. Death — 1 report (12.5%)
  3. Hypotension — 1 report (12.5%)
  4. Impaired Healing — 1 report (12.5%)
  5. Liver Disorder — 1 report (12.5%)
  6. Post Procedural Haemorrhage — 1 report (12.5%)
  7. Pulmonary Embolism — 1 report (12.5%)
  8. Renal Tubular Necrosis — 1 report (12.5%)

Source database →

Tacrolimus Sustained-release Capsules in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Tacrolimus Sustained-release Capsules approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Tacrolimus Sustained-release Capsules in United States?

RenJi Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.